ArticleAntimicrobial agents and chemotherapy2006
Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Fluoroquinolone-related adverse events resulting in health service use and costs: A systematic review.PloS one · 2019Pooled it
- Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection.Antimicrobial agents and chemotherapy · 2013Pooled it
- Safety of fluoroquinolones.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024Review
- Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile?Pharmaceutics · 2023Review
- Antibiotic-Specific Risk for Community-AcquiredAntimicrobial agents and chemotherapy · 2022Article
- Corticosteroids Do Not Increase the Likelihood of PrimaryOpen forum infectious diseases · 2021Article
- Antibiotic Prescribing Choices and Their Comparative C. Difficile Infection Risks: A Longitudinal Case-Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Effects of ciprofloxacin on the expression and production of exotoxins by Clostridium difficile.Journal of medical microbiology · 2013Article
- Clostridium difficile-associated diarrhea in a tertiary care medical center.Proceedings (Baylor University. Medical Center) · 2010Article
- Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.Drug safety · 2009Review
- Increase in Clostridium difficile-related mortality rates, United States, 1999-2004.Emerging infectious diseases · 2007Article
- Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK.Emerging infectious diseases · 2007Article
- Antibacterial discovery and development--the failure of success?Nature biotechnology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited evidence suggests that broad-spectrum fluoroquinolones such as gatifloxacin and moxifloxacin are more likely to cause Clostridium difficile-associated disease than levofloxacin. In a population-based case-control study of outpatients prescribed fluoroquinolones, we found no increased risk of C. difficile-associated disease requiring hospitalization among patients prescribed gatifloxacin or moxifloxacin compared to levofloxacin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.